Addex Therapeutics Net Worth
Addex Therapeutics Net Worth Breakdown | ADXN |
Addex Therapeutics Net Worth Analysis
Addex Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Addex Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Addex Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Addex Therapeutics' net worth analysis. One common approach is to calculate Addex Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Addex Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Addex Therapeutics' net worth. This approach calculates the present value of Addex Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Addex Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Addex Therapeutics' net worth. This involves comparing Addex Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Addex Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Addex Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Addex Therapeutics' net worth research are outlined below:
Addex Therapeutics generated a negative expected return over the last 90 days | |
Addex Therapeutics has high historical volatility and very poor performance | |
The company reported the previous year's revenue of 1.61 M. Net Loss for the year was (10.56 M) with profit before overhead, payroll, taxes, and interest of 1.44 M. | |
Addex Therapeutics currently holds about 8.81 M in cash with (7.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.4. | |
Addex Therapeutics has a poor financial position based on the latest SEC disclosures | |
Latest headline from news.google.com: Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - Marketscreener.com |
Addex Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Addex Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Addex Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
4th of April 2024 Upcoming Quarterly Report | View | |
9th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
4th of April 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Know Addex Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Addex Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Addex Therapeutics backward and forwards among themselves. Addex Therapeutics' institutional investor refers to the entity that pools money to purchase Addex Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Adar1 Capital Management Llc | 2024-09-30 | 1000 | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 353 | Rhumbline Advisers | 2024-09-30 | 35.0 |
Follow Addex Therapeutics' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 8.72 M.Market Cap |
|
Project Addex Therapeutics' profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (2.27) | (2.16) | |
Return On Capital Employed | (5.90) | (5.60) | |
Return On Assets | (2.27) | (2.16) | |
Return On Equity | (9.22) | (8.75) |
When accessing Addex Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Addex Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Addex Therapeutics' profitability and make more informed investment decisions.
Evaluate Addex Therapeutics' management efficiency
Addex Therapeutics has return on total asset (ROA) of (0.6171) % which means that it has lost $0.6171 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2629) %, meaning that it created substantial loss on money invested by shareholders. Addex Therapeutics' management efficiency ratios could be used to measure how well Addex Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 12th of December 2024, Return On Tangible Assets is likely to grow to -2.16. In addition to that, Return On Capital Employed is likely to grow to -5.6. At this time, Addex Therapeutics' Intangible Assets are very stable compared to the past year. As of the 12th of December 2024, Other Assets is likely to grow to about 66 K, while Total Assets are likely to drop about 4.4 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | 0.02 | 0.01 | |
Tangible Book Value Per Share | 0.02 | 0.01 | |
Enterprise Value Over EBITDA | 0.01 | 0.01 | |
Price Book Value Ratio | 2.98 | 2.83 | |
Enterprise Value Multiple | 0.01 | 0.01 | |
Price Fair Value | 2.98 | 2.83 | |
Enterprise Value | -103 K | -97.8 K |
The management strategies employed by Addex Therapeutics' are designed to enhance shareholder value and ensure long-term growth. We assess the effectiveness of these strategies in our stock analysis.
Enterprise Value Revenue 7.888 | Revenue 863.2 K | Quarterly Revenue Growth (0.82) | Revenue Per Share 1.2 | Return On Equity (1.26) |
Addex Therapeutics Corporate Filings
6K | 22nd of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
F3 | 14th of August 2024 An amendment to the original Schedule 13D filing | ViewVerify |
24th of April 2024 Other Reports | ViewVerify |
Addex Therapeutics Earnings per Share Projection vs Actual
Addex Therapeutics Corporate Management
Timothy Dyer | CEO CoFounder | Profile | |
Werner Henrichi | Consultant | Profile | |
Mikhail Kalinichev | Head Science | Profile | |
JeanPhilippe Rocher | Head Chemistry | Profile | |
Roger MD | Chief Director | Profile | |
Lnaic Teyssdou | Head Finance | Profile | |
Robert Lutjens | Head Biology | Profile |
Already Invested in Addex Therapeutics?
The danger of trading Addex Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Addex Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Addex Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Addex Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Addex Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Addex Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Addex Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Addex Therapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Addex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Addex Therapeutics. If investors know Addex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Addex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (21.75) | Revenue Per Share 1.2 | Quarterly Revenue Growth (0.82) | Return On Assets (0.62) | Return On Equity (1.26) |
The market value of Addex Therapeutics is measured differently than its book value, which is the value of Addex that is recorded on the company's balance sheet. Investors also form their own opinion of Addex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Addex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Addex Therapeutics' market value can be influenced by many factors that don't directly affect Addex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Addex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Addex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Addex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.